Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Drug

Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer

Fineline Cube Feb 13, 2026
Company Drug

RemeGen’s Telitacicept Receives FDA Orphan Drug Designation for Myasthenia Gravis

Fineline Cube Oct 13, 2022

China-based pharma firm RemeGen (HKG: 9995, SHA: 688331) has announced receiving Orphan Drug Designation (ODD)...

Company Deals

Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study

Fineline Cube Oct 13, 2022

China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership...

Company Medical Device

Hotgen Biotech Gains Regulatory Approvals in Saudi Arabia and India

Fineline Cube Oct 13, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced receiving one certificate from the Saudi...

Company Drug

BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study

Fineline Cube Oct 13, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its Bruton’s...

Company

Hengrui Medicine’s Deputy GM Tao Weikang Resigns, Joins Qilu Pharma

Fineline Cube Oct 13, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its deputy general manager...

Company Deals

Proxinse Medtech Raises Series A Funding for Endoscope Camera System

Fineline Cube Oct 13, 2022

Shenzhen Proxinse Medical Technology Co., Ltd, a provider of minimally invasive surgery endoscope camera systems...

Company Deals

AlphaLife Sciences Raises Series A+ Funding for Clinical Research SaaS

Fineline Cube Oct 13, 2022

China-based clinical research SaaS service provider AlphaLife Sciences has reportedly raised “tens of millions” of...

Company Drug

Aosaikang’s Neratinib Maleate API Market Filing Accepted by NMPA

Fineline Cube Oct 13, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the market filing for its...

Drug Policy / Regulatory

Azvudine Included in China’s COVID-19 Treatment Protocol

Fineline Cube Oct 12, 2022

The National Healthcare Commission and the National Administration of Traditional Chinese Medicine have released a...

Company Drug

NMPA Approves IND Filing for Henan Genuine Biotech’s Long-Acting HIV Drug CL-197

Fineline Cube Oct 12, 2022

China-based Henan Genuine Biotech Co., Ltd’s investigational new drug (IND) filing for its oral long-acting...

Company Deals

WuXi Biologics Partners with Toregem BioPharma on Anti-USAG-1 Monoclonal Antibody

Fineline Cube Oct 12, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...

Company Deals

BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development

Fineline Cube Oct 12, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership...

Company Medical Device

NMPA Approves Beijing Union Strong’s Intracranial Aneurysm Surgical Planning Software

Fineline Cube Oct 12, 2022

The National Medical Products Administration (NMPA) has approved the marketing of Beijing Union Strong Technology...

Company Deals

Aier Eye Hospital Group Plans IPO on ChiNext Board

Fineline Cube Oct 12, 2022

China-based ophthalmic medical services provider Aier Eye Hospital Group Co., Ltd (SHE: 300015) is set...

Company Deals

BeiGene Partners with Immune-Onc for Clinical Development of Myeloid Checkpoint Inhibitors

Fineline Cube Oct 12, 2022

China-based biotech BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a clinical study...

Company Deals

Cyagen Biosciences Partners with Neurophth for Ophthalmology AAV Capsid Development

Fineline Cube Oct 12, 2022

Cyagen Biosciences, a provider of custom-engineered mouse and rat models with operations in the US...

Company Deals

IASO Biotherapeutics Licenses CD19 Binder to Cabaletta Bio for Autoimmune Diseases

Fineline Cube Oct 12, 2022

China-based IASO Biotherapeutics has announced a licensing agreement with US firm Cabaletta Bio Inc. (NASDAQ:...

Company Drug

Henlius Biotech’s HanBeiTai Biosimilar Accepted for Review by CDE

Fineline Cube Oct 12, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...

Hospital Policy / Regulatory

Shanghai Launches High-Quality Development Pilot for Public Hospitals

Fineline Cube Oct 12, 2022

The Shanghai Municipal Health Commission (SHC) has released a notification regarding the public hospital high-quality...

Drug Policy / Regulatory

NMPA Introduces Electronic Certificates for Biologics and Narcotic Drugs

Fineline Cube Oct 12, 2022

The National Medical Products Administration (NMPA) has released a notification regarding the initiation of electronic...

Posts pagination

1 … 574 575 576 … 624

Recent updates

  • CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility
  • GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%
  • Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play
  • China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
  • Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility

Company

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

Company Medical Device

Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.